fluoxetine has been researched along with venlafaxine in 25 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.00) | 18.2507 |
2000's | 9 (36.00) | 29.6817 |
2010's | 15 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carlier, PR; Lo, MM; Lo, PC; Reynolds, IJ; Richelson, E; Sharma, TA; Tatsumi, M | 1 |
Topliss, JG; Yoshida, F | 1 |
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J | 1 |
Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Belardi, JK; Bray, JA; Burroughs, KD; Cohn, ST; Cosmi, SA; Deecher, DC; Gavrin, LK; Ho, DM; Johnston, GH; Koury, EJ; Leiter, J; Leventhal, L; Mahaney, PE; Mugford, CA; Platt, B; Rosenzweig-Lipson, SJ; Sabatucci, JP; Santilli, AA; Smith, VA; Stack, GP; Trybulski, EJ; Vu, TA; Ye, F; Zhang, Y | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Curcio, R; Nicoli, R; Rudaz, S; Veuthey, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Burroughs, K; Cosmi, S; Deecher, DC; Ho, D; Johnston, G; Leiter, J; Mahaney, PE; Sabatucci, JP; Trybulski, E; Zhang, Y | 1 |
Cho, JW; Chung, CM; Kim, HH; Lee, HY; Lee, KH; Min, KH; Nam, HS; Park, CE; Ryu, EJ; Shin, YJ; Yoon, HJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Jung, ME; Kang, SY; Kim, HJ; Kim, J; Kim, MJ; Kim, MS; Lee, J; Lee, KN; Lee, M; Lee, SH; Park, EJ; Park, WK; Seo, HJ; Son, EJ | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Arunotayanun, W; Dalley, JW; Gibbons, S; Huang, XP; Iversen, L; Roth, BL; Setola, V; Treble, R | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Choi, Y; Raymer, BK | 1 |
2 review(s) available for fluoxetine and venlafaxine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Sleep modulating agents.
Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents | 2019 |
23 other study(ies) available for fluoxetine and venlafaxine
Article | Year |
---|---|
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
Topics: Amino Alcohols; Animals; Antidepressive Agents; Dopamine; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Serotonin; Species Specificity | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Inhibition of P-glycoprotein by newer antidepressants.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection | 2003 |
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
Topics: Animals; Cell Line; Cyclohexanols; Ethylamines; Female; Humans; Male; Mice; Models, Molecular; Molecular Structure; Norepinephrine; Pain; Rats; Structure-Activity Relationship; Symporters | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Development of an in-capillary approach to nanoscale automated in vitro cytochromes p450 assays.
Topics: Autoanalysis; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Fluoxetine; Humans; Isoenzymes; Mass Spectrometry; Pharmaceutical Preparations; Quinidine; Recombinant Proteins; Solutions; Venlafaxine Hydrochloride | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
Topics: Animals; Crystallography, X-Ray; Ethylamines; Humans; Molecular Conformation; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Rats; Structure-Activity Relationship; Thiophenes | 2010 |
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Antidepressive Agents; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dopamine; Humans; Mice; Neurotransmitter Uptake Inhibitors; Norepinephrine; Propylamines; Rats; Serotonin; Tetrazoles | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
Topics: Animals; Antidepressive Agents; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Mice; Motor Activity; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Topics: Allyl Compounds; HEK293 Cells; Humans; Indoles; Magnetic Resonance Spectroscopy; Molecular Conformation; Propylamines; Protein Binding; Psychotropic Drugs; Receptors, Serotonin; Serotonin Receptor Agonists; Spectrophotometry, Ultraviolet; Tryptamines | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship | 2014 |